Ionis Pharmaceuticals (NASDAQ: IONS) has had plenty of good news over the last couple of months:
But the best is yet to come for the biotech.
Ionis Pharmaceuticals (NASDAQ: IONS) has had plenty of good news over the last couple of months:
But the best is yet to come for the biotech.